You are here

Improved Formulations to Enhance Bio-availability for Antisense Therapeutics

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: HDTRA1-10-P-0041
Agency Tracking Number: C101-102-0079
Amount: $70,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD10-102
Solicitation Number: 2010.1
Timeline
Solicitation Year: 2010
Award Year: 2010
Award Start Date (Proposal Award Date): 2010-05-17
Award End Date (Contract End Date): 2010-11-16
Small Business Information
4701 Innovation Drive
Lincoln, NE 68521
United States
DUNS: 131068186
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: Yes
Principal Investigator
 Luis Nunez
 Chief Technology Officers
 (630) 854-8173
 luisteo@aol.com
Business Contact
 Gus Larsen
Title: CEO
Phone: (402) 416-1811
Email: lnkchemsolutions@aim.com
Research Institution
N/A
Abstract

In general, many biological and chemical agents affect the lungs directly or indirectly, even if the respiratory system is not the primary target organ of a military or terrorist attack. Both in the case of military and civilian attacks the lung can be one of the first organs affected by a chemical or biological agent. LNK Chemsolutions (LNK) with expertise in nanoparticle formulations and the University of Illinois Chicago with expertise in Acute Lung Injury (ALI) molecular biology and treatment modality development have teamed up to develop novel oral and inhalation formulation of targeted nanoparticles (NPs) containing siRNA and/or miRNA to improve the treatment of ALI unobtainable with current delivery systems.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government